Ori-A-631

N/A

Report date: 2022/07/21 14:22:51

Base Information

Drug NameOri-A-631

Drug Alias NameOri-A-631OriA-631Ori-A631

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-5'-nucleotidaseAnti-Ectonucleoside triphosphate diphosphohydrolase 1

Targets5'-nucleotidaseEctonucleoside triphosphate diphosphohydrolase 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOriCell Therapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesOriCell Therapeutics Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A